Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis
- PMID: 21256121
- DOI: 10.1016/j.brainres.2011.01.036
Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis
Abstract
Endogenous opioids inhibit the onset and progression of experimental autoimmune encephalomyelitis (EAE) with 30days of treatment. This study examined the long term effects of the opioid growth factor (OGF, [Met(5)]-enkephalin) and a low dose of the opioid antagonist naltrexone (LDN) on expression of myelin oligodendrocyte glycoprotein (MOG)-induced EAE. C57BL/6 mice began receiving daily injections of 10mg/kg OGF (MOG+OGF), 0.1mg/kg naltrexone (MOG+LDN), or saline (MOG+Vehicle) at the time of EAE induction and continuing for 60days. In contrast to 100% of the MOG+Vehicle group with behavioral symptoms of EAE, 63% and 68% of the MOG+OGF and MOG+LDN mice expressed disease. Both severity and disease indices of EAE in OGF- and LDN-treated mice were notably decreased from MOG+Vehicle cohorts. By day 60, 6- and 3-fold more animals in the MOG+OGF and MOG+LDN groups, respectively, had a remission compared to MOG+Vehicle mice. Neuropathological studies revealed i) astrocyte activation and neuronal damage as early as day 10 (prior to behavioral symptoms) in all MOG-injected groups, ii) a significant reduction of activated astrocytes in MOG+OGF and MOG+LDN groups compared to MOG+Vehicle mice at day 30, and iii) no demyelination on day 60 in mice treated with OGF or LDN and not displaying disease symptoms. These results indicate that treatment with OGF or LDN had no deleterious long-term repercussions and did not exacerbate EAE, but i) halted progression of disease, ii) reversed neurological deficits, and iii) prevented the onset of neurological dysfunction across a considerable span of time.
Copyright © 2011 Elsevier B.V. All rights reserved.
Similar articles
-
Intermittent blockade of OGFr and treatment of autoimmune disorders.Exp Biol Med (Maywood). 2018 Dec;243(17-18):1323-1330. doi: 10.1177/1535370218817746. Epub 2018 Dec 12. Exp Biol Med (Maywood). 2018. PMID: 30541348 Free PMC article. Review.
-
Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis.Brain Res. 2010 Jan 15;1310:154-61. doi: 10.1016/j.brainres.2009.11.026. Epub 2009 Nov 18. Brain Res. 2010. PMID: 19931226
-
Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis.Exp Biol Med (Maywood). 2009 Nov;234(11):1383-92. doi: 10.3181/0906-RM-189. Exp Biol Med (Maywood). 2009. PMID: 19855075
-
Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established experimental autoimmune encephalomyelitis.Brain Res. 2012 Sep 7;1472:138-48. doi: 10.1016/j.brainres.2012.07.006. Epub 2012 Jul 20. Brain Res. 2012. PMID: 22820301
-
Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy.Int Immunopharmacol. 2019 Oct;75:105785. doi: 10.1016/j.intimp.2019.105785. Epub 2019 Aug 9. Int Immunopharmacol. 2019. PMID: 31404891 Review.
Cited by
-
Enkephalins and Pain Modulation: Mechanisms of Action and Therapeutic Perspectives.Biomolecules. 2024 Jul 30;14(8):926. doi: 10.3390/biom14080926. Biomolecules. 2024. PMID: 39199314 Free PMC article. Review.
-
Multiple Sclerosis and the Endogenous Opioid System.Front Neurosci. 2021 Sep 17;15:741503. doi: 10.3389/fnins.2021.741503. eCollection 2021. Front Neurosci. 2021. PMID: 34602975 Free PMC article. Review.
-
The Effects of Low Dose Naltrexone on Opioid Induced Hyperalgesia and Fibromyalgia.Front Psychiatry. 2021 Feb 16;12:593842. doi: 10.3389/fpsyt.2021.593842. eCollection 2021. Front Psychiatry. 2021. PMID: 33664680 Free PMC article.
-
Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study.PLoS One. 2019 Feb 14;14(2):e0212460. doi: 10.1371/journal.pone.0212460. eCollection 2019. PLoS One. 2019. PMID: 30763385 Free PMC article.
-
Intermittent blockade of OGFr and treatment of autoimmune disorders.Exp Biol Med (Maywood). 2018 Dec;243(17-18):1323-1330. doi: 10.1177/1535370218817746. Epub 2018 Dec 12. Exp Biol Med (Maywood). 2018. PMID: 30541348 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous